Not finding it? Sign in to also search OpenAlex live.
-
Analysis of Ratio and Phase Errors over Time for Low Power Voltage Transformers2020 IEEE International Instrumentation and Measurement Technology Conference conference-paper Engineering Advanced Electrical Measurement Techniques
Alessandro Mingotti, Lorenzo Peretto, Andrea Nalli, Marco Pau, Ferdinanda Ponci
4citations -
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer − PORTEC-4a an international, randomised, phase 3 trial2026 Radiotherapy and Oncology article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access
Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A.D. Haverkort, Nienke Kuijsters, Stefan Kommoss, Friederike L.A. Koppe, +24 more
3citations -
1628MO A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
Georgios Kantidakis, Saskia Litière, Anouk Neven, Marie Vinches, Ian Robert Judson, Patrick Schöffski, +7 more
0citations -
7425 Biochemical Response, Symptom Control, and Safety of Oral Octreotide Capsules Treatment in Acromegaly: A Post Hoc Analysis of a Large Pooled Database from Three Phase 3 Clinical Trials2024 Journal of the Endocrine Society article Medicine Pituitary Gland Disorders and Treatments Open access
Maria Fleseriu, Susan Leanne Samson, Nienke Ruurdje Biermasz, Christian Joseph Strasburger, Shir Fuchs Orenbach, Jason A. Crompton, +1 more
0citations -
Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry2023 American Journal of Therapeutics article Medicine Atrial Fibrillation Management and Outcomes Open access
Jutta K Bergler-Klein, Nina N. Gotcheva, Oskars Kalējs, Zbigniew F. Kalarus, Dragan Kovačić, Viktor Peršić, +5 more
0citations -
Combination of enteral and parenteral nutrition in the acute phase of critical illness: An updated systematic review and meta‐analysis2021 Journal of Parenteral and Enteral Nutrition review Nursing Clinical Nutrition and Gastroenterology Open access
Aileen Hill, Daren Keith Heyland, Luis Ortiz‐Reyes, Elena Laaf, Gunnar Elke, Christian Stoppe
59citations -
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
Pasi Antero Janne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, +13 more
35citations -
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial2023 Annals of Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Steffen Koschmieder, Susanne Isfort, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, +8 more
13citations -
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study2021 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Raymond L. Comenzo, Giovanni O. Palladini, Efstathios Kastritis, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, +24 more
12citations -
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Patrick Schöffski, Suzanne George, Michael Charles Heinrich, John Raymond Zalcberg, Sebastian Bauer, Hans A. J. Gelderblom, +12 more
10citations -
Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Florian Heinrich Heidel, Andreas Hochhaus, Heiko Becker, Philipp Jakob Jost, +19 more
3citations -
The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
Régis Peffault de Latour, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yutaka Ueda, Carlos de Castro, Samopriyo Maitra, +3 more
1citations -
P271 To what extent are baseline characteristics in biologic-experienced patients with psoriatic arthritis associated with achievement of minimal disease activity at week 24 of guselkumab treatment: a post hoc analysis of the phase IIIb COSMOS clinical trial
William L. Tillett, Sarah Ohrndorf, Julio A. Ramírez, Marlies Neuhold, Robert Wapenaar, Elke Theander, +4 more
0citations -
Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Andrew Jay Portuguese, Sherilyn Alvaran Tuazon, Margot J. Pont, Gabriel O. Cole, Blythe Duke Sather, Xiaoling Song, +17 more
0citations